RPE65 and Leber congenital amaurosis: Currently, there are more than 10 clinical trials exploring the effectiveness and safety of a subretinal (SR) injection of AAV2 vectors carrying RPE65 cDNA for LCA cases with biallelic RPE65 mutations.